Investors

NextCell is listed on Nasdaq First North Growth Market. The drug candidate ProTrans is a platform technology aimed at developing cell therapies to treat autoimmune diseases and other inflammatory conditions.

The company's primary indication is type 1 diabetes, where both safety and effectiveness concerning the preservation of patients' ability to produce their own insulin have been demonstrated in clinical drug trials with their drug candidate, ProTrans. The company's other business area, Cellaviva, represents Scandinavia's largest family preservation of stem cells.

Here, you can find the financial calendar, reports, stock information, and corporate governance details.

‍IR-contact: Patrik Fagerholm, +46 8 735 55 95 patrik.fagerholm@nextcellpharma.com

NextCell as an investment

NextCell develops pioneering cell therapies for the treatment of autoimmune and inflammatory disorders. NextCell's drug candidate, ProTrans, is at thefore front of the company's development for the treatment of type 1 diabetes.

ProTrans is NextCell's first drug candidate, based on the company's proprietary selection algorithm and platform technology. The primary indication is for the treatment of newly diagnosed type 1 diabetes. The efficacy of ProTrans can also be beneficial in a variety of other areas where there are currently no suitable options. Examples encompass conditions such as Crohn's disease, multiplesclerosis (MS), and rheumatism.

Effective and safe treatment of type 1 diabetes

NextCell has developed ProTrans, a truly off-the-shelf cell therapy product. Topline data from the phase 2 trial shows that disease progression can be stopped for a year by a single infusion of ProTrans, and patients treated did not require increased doses of insulin.
Long-term follow-up of patients is ongoing, with data proposing that a single infusion can delay a 50% reduction of endogenous insulin for 3 years. No severe adverse reaction has been registered to date in any clinical trial with ProTrans.

Patented platform technology

NextCell’s patented selection algorithm distinguishes ProTrans from other treatments by identifying the optimal cells for treatment for the specific disease.
ProTrans is NextCell’s first drug candidate based on this platform technology. The algorithm can be utilized in other autoimmune diseases and inflammatory disorders such as Crohn’s disease, multiple sclerosis (MS), and rheumatism.

Type 1 diabetes market

Every year, an estimated 500 000 people are diagnosed with type 1 diabetes worldwide. ProTrans can target a fifth of these patients providing a market value of 8-10 billion USD.
The first immunosuppressive drug approved in US for type 1 diabetes was Tzield (Teplizumab, marketed by Sanofi). This is positive since ProTrans is at least similar in efficacy as Tzield, but ProTrans has a superior safety profile and can be priced very competitively. The cost of therapy with ProTrans runs at 80-100,000 USD per patient compared to ca 200,000 USD per patient for Tzield.

Investigator initiated trials

NextCell’s drug candidate, ProTrans has gained recognition in the academic community. Uppsala University is sponsoring a paediatric trial treating a total of 66 children and adolescent patients with type 1 diabetes. NextCell provides ProTrans in return for clinical data, important for the regulatory pathway, and to bring ProTrans to the market for type 1 diabetes patients.
The well renowned McGill University in Montreal, Canada, is sponsoring a Phase 2 clinical trial in patients with COVID-19 induced severe pneumonia.

Marketing authorisation approval

NextCell has participated in a scientific advisory discussion with the European Medicines Agency (EMA) to develop a go-to-market strategy for ProTrans.
NextCell plans to co-develop ProTrans with external partners through the initiation of Phase 3 trials.

Cellaviva increases market share

Cellaviva is NextCell's stem cell bank, which offers expectant parents the opportunity to preserve and store stem cells from umbilical cord blood and tissue for possible future medical needs – the largest in Scandinavia. The number of customers has increase year to year.

Financial calendar

Year End Report 2024

October 24, 2024

Annual General Meeting

November 27, 2024

Q1 report 2025

January 30, 2025

Q2 report 2025

April 25, 2025

Q3 report 2025

July 24, 2025

Financial reports

2028

No reports published yet.

2027

No reports published yet.

2026

No reports published yet.

2025

No reports published yet.

Corporate Governance

Auditor

‍Öhrlings PricewaterhouseCoopers AB (PwC)
Torsgatan 21, 113 97 Stockholm

PwC has been the company's auditor since 2014. The primary auditor, since 2018, is Johan Engstam. Johan Engstam is an Authorized Public Accountant and a member of FAR, the institute for the accountancy profession in Sweden.

Articles Of Association

Download

Annual Meetings

Annual Shareholders Meeting 2024

Kallelse årsstämma

27/11/2024

Fullmaktsformulär bolagsstämma 2024

27/11/2024

Annual Shareholders Meeting 2023

Kallelse årsstämma 2023

30/11/2023

Fullmaktsformulär årsstämma 2023

30/11/2023

Annual Meeting 2022

Fullmaktsformulär årsstämma 2022

24/11/2022

Kallelse till årsstämma 2022

24/11/2022

Annual Meeting 2021

Kallelse till årsstämma 2021

24/11/2021

Fullmaktsformulär

24/11/2021

Annual Meeting 2020

Fullmaktsformulär

24/11/2020

Kallelse till årsstämma 2020

24/11/2020

Kommuniké från årsstämma

24/11/2020

Annual Meeting 2019

Power of attorney – Annual general meeting 2019

5/12/2019

Notice to attend Annual General Meeting 2019

5/12/2019

Fullständiga handlingar inför årsstämma

5/12/2019

Annual Meeting 2018

Power of attorney – Annual general meeting 2018

5/12/2018

Notice to attend Annual General Meeting 2018

5/12/2018

Kommuniké från årsstämma 2018

5/12/2018

Full list of resolutions ahead of Annual General Meeting 2018

5/12/2018

Annual report (audited)

5/12/2018

Annual Meeting 2017

Proxy form for Annual General Meeting of NextCell Pharma AB on 24 February 2017 extraordinary

24/2/2017

Notice to attend Annual General Meeting of NextCell Pharma AB on 24 February 2017

24/2/2017

Full list of resolutions ahead of Annual General Meeting of NextCell Pharma AB on 24 February 2017

24/2/2017

Power of attorney – Annual general meeting 2017

5/12/2017

Kommuniké från årsstämma 2017

5/12/2017

Certified Adviser

FNCA Sweden AB

Address: Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm

Phone: +46(0)8-528 00 399

Mail: info@fnca.se

The Share

Shareholders

List of 10 largest shareholders as of August 31, 2024

‍

Owner

Percentage

Försäkringsbolaget Avanza Pension

11,404,012

15.6

Diamyd Medical AB

5,227,258

7.2

Ålandsbanken i ägares ställe

2,838,584

5.8

Nordnet Pensionsförsäkring AB

2,414,781

3.3

Pabros AB

1,779,649

2.4

Martin Larsen

1,600,000

2.2

Anders Essen-Möller*

1,587,325

2.2

Nordea Livförsäkring Sverige AB

1,223,913

1.7

Clearstream banking

1,175,517

1.6

Filip Wirefors

1,082,000

1.5

Total

30,333,039

41.5

* In addition to Chairman of the Board, Anders Essen-Möller's directly registered holdings, this item includes holdings of 4.09 percent managed by Avanza Pension.

Trading information

NextCell Pharma AB is listed on the Nasdaq First North Growth Market since July 2020. The stock is traded under the ticker “NXTCL”. ISIN Code: SE0009723125.

The current share price is available on Nasdaq First North website:

Nasdaq OMX Nordic

Dividend policy

NextCell has to date paid no dividends to its shareholders. The company is in a development phase, and any surplus is primarily planned for reinvestment in the company’s development.